Hoque, Ashraful, Yao, Song, Till, Cathee, Kristal, Alan R., Goodman, Phyllis J., Hsing, Ann W., Tangen, Catherine M., Platz, Elizabeth A., Stanczyk, Frank Z., Reichardt, Juergen K.V., vanBokhoven, Adrie, Neuhouser, Marian L., Santella, Regina M., Figg, William D., Price, Douglas K., Parnes, Howard L., Lippman, Scott M., Ambrosone, Christine B., and Thompson, Ian (2015) Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology, 85 (3). pp. 616-620.

Chau, Cindy H., Price, Douglas K., Till, Cathee, Goodman, Phyllis J., Chen, Xiaohong, Leach, Robin J., Johnson-Pais, Teresa L., Hsing, Ann W., Hoque, Ashraful, Tangen, Catherine M., Chu, Lisa, Parnes, Howard L., Schenk, Jeannette M., Reichardt, Juergen K.V., Thompson, Ian M., and Figg, William D. (2015) Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PLoS One, 10 (5). e0126672.

Figg, William D., Chau, Cindy H., Price, Douglas K., Till, Cathee, Goodman, Phyllis J., Cho, Yonggon, Varella-Garcia, Marileila, Reichardt, Juergen K.V., Tangen, Catherine M., Leach, Robin J., van Brokhoven, Adrie, Thompson, Ian M., and Lucia, M. Scott (2014) Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial. Urology, 84 (1). pp. 127-131.

Yao, Song, Till, Cathee, Kristal, Alan R., Goodman, Phyllis J., Hsing, Ann W., Tangen, Catherine M., Platz, Elizabeth A., Stanczyk, Frank Z., Reichardt, Juergen, Tang, Li, Neuhouser, Marian L., Santella, Regina M., Figg, William D., Price, Douglas K., Parnes, Howard L,, Lippman, Scott M., Thompson, Ian M., Ambrosone, Christine B., and Hoque, Ashraful (2011) Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer causes and control, 22 (8). pp. 1121-1131.